Here’s Why Stevanato Group Spa (STVN) Declined in Q1

Conestoga Capital Advisors, an asset management company, released its first-quarter 2026 investor letter. A copy of the letter can be downloaded here. The first quarter of 2026 began with optimism about the domestic economy and attractive Small Cap valuations, but was impacted by volatility from Middle East geopolitical unrest and changing interest rate expectations. This unrest drove energy prices up and created cautious global markets. Energy, Basic Materials, and Industrials performed well, while software companies faced challenges due to AI disruption concerns. Market sensitivity to geopolitical events, energy prices, and inflation remains high. The Conestoga Small Cap Composite fell 5.01%, underperforming the Russell 2000 Growth’s -2.81% return. The decline was driven by negative stock selection and headwinds in Technology and Health Care, with sector allocation benefits insufficient to offset losses. In addition, please check the Strategy’s top five holdings to know its best picks in 2026.

In its first-quarter 2026 investor letter, Conestoga Capital Advisors highlighted stocks like Stevanato Group S.p.A. (NYSE:STVN). Stevanato Group S.p.A. (NYSE:STVN) is an Italian company that designs and distributes products and processes to offer integrated solutions for the biopharma and healthcare industries. On April 24, 2026, Stevanato Group S.p.A. (NYSE:STVN) closed at $16.18 per share. One-month return of Stevanato Group S.p.A. (NYSE:STVN) was 20.12%, and its shares lost 25.02% over the past 52 weeks. Stevanato Group S.p.A. (NYSE:STVN) has a market capitalization of about $4.42 billion.

Conestoga Capital Advisors stated the following regarding Stevanato Group S.p.A. (NYSE:STVN) in its Q1 2026 investor letter:

“Stevanato Group S.p.A. (NYSE:STVN) provides drug containment and delivery solutions to pharmaceutical and biotechnology companies. The stock struggled as investors weighed solid results against a mixed underlying business mix and moderating growth profile. While margins improved and high-value solutions continued to scale, overall revenue growth remained relatively modest at 5% in the quarter. Continued weakness in the Engineering segment and a transition toward higher value products contributed to a more tempered market reaction. The stock is also pressured by the decline of oral vs. GLP-1s.”

Stevanato Group S.p.A. (NYSE:STVN) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 15 hedge fund portfolios held Stevanato Group S.p.A. (NYSE:STVN) at the end of the fourth quarter, up from 13 in the previous quarter. In Q4 2025, Stevanato Group S.p.A.’s (NYSE:STVN) revenue grew 7% at constant currency and 5% on a reported basis to $346.5 million. While we acknowledge the potential of Stevanato Group S.p.A. (NYSE:STVN) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.